A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

NCT03283696 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Soft Tissue Sarcoma

Interventions

DRUG: Olaratumab
DRUG: Doxorubicin
DRUG: Ifosfamide
DRUG: Mesna

Sponsor

Eli Lilly and Company